(143 days)
Not Found
Unknown
The document describes automated segmentation and quantification features ("Lung Lobe Quantification", "TumorFinder") which could potentially utilize AI/ML, but the description does not explicitly mention these technologies. The validation studies focus on calculation accuracy rather than performance metrics typically associated with AI/ML models.
No
The device is a medical imaging processing and analysis software, not a therapeutic device. While it aids in treatment planning (SIRT), it does not directly apply therapy.
Yes
The device processes, displays, and manages medical imaging data, offering tools like "Lung Lobe Quantification" and "TumorFinder" that provide quantitative analysis and segmentation of medical images, which are essential steps in diagnosing various conditions.
Yes
The device description explicitly states it is a "reading and processing module" and describes software functionalities for processing, displaying, and managing medical imaging data. The performance studies focus on validating calculations against spreadsheets, further indicating a software-based function. There is no mention of hardware components included with the device.
Based on the provided information, this device is not an In Vitro Diagnostic (IVD).
Here's why:
- IVDs analyze biological samples: IVDs are designed to examine specimens taken from the human body, such as blood, urine, tissue, etc., to provide information about a person's health.
- This device analyzes medical images: The description clearly states that the device processes, displays, and manages nuclear medicine and other medical imaging data (PET/CT/MR/SPECT). It works with images, not biological samples.
- The functions are image processing and analysis: The features described, such as multi-modal coregistration, fusion, segmentation, quantification of lung lobes, tumor finding based on image criteria, and SIRT planning based on imaging, are all related to the manipulation and analysis of medical images.
Therefore, while this is a medical device used in the diagnostic process, it falls under the category of medical imaging software or a picture archiving and communication system (PACS) component, not an In Vitro Diagnostic.
N/A
Intended Use / Indications for Use
Hybrid3D that provides software applications used to process, display, and manage nuclear medicine and other medical imaging data transferred from other workstation or acquisition stations.
Product codes (comma separated list FDA assigned to the subject device)
KPS
Device Description
HERMES Hybrid3D is a reading and processing module for the advanced needs in medical imaging. It offers multi-modal (PET/CT/MR/SPECT) coregistration and interactive fusion of multiple datasets. HybridViewer 3D handles viewing and fusion of multi-sequence MRI studies with oblique orientation and allows switching between original and standard TCS view orientation as well as defining own slice directions. 3D seqmentation, cropping and interpolation techniques allow complex tasks in VOI definition and can cover cases like cavities, splitting structures into subsections or logic operations (compute intersections, merge, grow). Results can be imported and exported as DICOM and are therefore available for research in 3rd party tools. Additionally, it provides tools for advanced 3D fusion rendering of studies and VOIs.
The Lung Lobe Quantification module in Hybrid3D, introduces an efficient and automated workflow solution to accurately compute 3D lobar anatomy from CT (with or without contrast). The workflow supports the addition of functional images (SPECT V/Q, SUV SPECT, CT iodine maps, hyperpolarized xenon MRI, etc.) to accurately relate lobar anatomy to function. No changes have been made to Lung Lobar Quantification since the previous release.
The Tumor Finder wizard provides automatic segmentation of lesions in a PET study or a combined PET/CT study pair, based on criteria relative to a background volume placed in the liver or mediastinum. This reduces the time required for tumor delineation. It also provides both visual and statistical evaluation of tumor burden, which helps with comparing follow up studies.
Selective Internal Radionuclide Therapy (SIRT), is currently used in the treatment of liver tumors either from primary liver cancer or metastatic disease (e.g. colorectal primary cancer). The SIRT wizard provides processing for SIRT planning and verification.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
multi-modal (PET/CT/MR/SPECT)
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Prescription Use
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Validation of the Hybrid3D SIRT has been made between the calculations performed by Hybrid3D and the results from spreadsheet calculations based on the formulae published by SIRTEX for the Resin Microspheres and BTG for the Glass Theraspheres.
- Lung Shunt was calculated from planar images. The results for Lung Shunt were identical.
- The Prescribed Activity for Planning using Resin Microspheres using the BSA method were identical to 2 decimal places
- The Activity to Implant for Planning using Glass Microspheres using the PTV method were identical to 2 decimal places
- The Voxel Dose measured from the PETDose Map was identical to 2 decimal places
- The Voxel Dose measured from the SPECT Dose Map varied by up to 5% because the methods used for normalization, by calculating the common field of view by the application and by the test procedure, differ slightly.
- The values for Maximum Dose and Dose at 90% Volume D90%(Gy) differ because of the inherent inaccuracy of reading values manually from the Dose Volume Histogram. The test was performed only to establish that there were no fundamental errors in the calculations.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 892.1200 Emission computed tomography system.
(a)
Identification. An emission computed tomography system is a device intended to detect the location and distribution of gamma ray- and positron-emitting radionuclides in the body and produce cross-sectional images through computer reconstruction of the data. This generic type of device may include signal analysis and display equipment, patient and equipment supports, radionuclide anatomical markers, component parts, and accessories.(b)
Classification. Class II.
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
October 25, 2018
HERMES MEDICAL SOLUTIONS AB % Mr. Joakim Arwidson Vice President Quality & Regulatory Affairs Strandbergsgatan 16 STOCKHOLM SWEDEN 11251
Re: K181468
Trade/Device Name: Hybrid3D Regulation Number: 21 CFR 892.1200 Regulation Name: Emission Computed Tomography System Regulatory Class: Class II Product Code: KPS Dated: August 20, 2018 Received: September 24, 2018
Dear Mr. Arwidson:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/ofdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part
1
801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.htm); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice
(https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
| Michael D. | Digitally signed by Michael D. O'hara -S
DN: c=US, o=U.S. Government, ou=HHS,
ou=FDA, ou=People,
0.9.2342.19200300.100.1.1=1300226759,
cn=Michael D. O'hara -S
Date: 2018.10.25 18:03:53 -04'00' |
|-----------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| O'hara -S | For |
| Robert A. Ochs, Ph.D. | |
| Director | |
| Division of Radiological Health | |
| Office of In Vitro Diagnostics
and Radiological Health | |
| Center for Devices and Radiological Health | |
Enclosure
2
Indications for Use
510(k) Number (if known) K181468
Device Name Hybrid3D
Indications for Use (Describe)
Hybrid3D that provides software applications used to process, display, and manage nuclear medicine and other medical imaging data transferred from other workstation or acquisition stations.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ------------------------------------------------- | -- |
X Prescription Use (Part 21 CFR 801 Subpart D)
| Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
5.0 510 (k) SUMMARY
A. Submitted by:
- Submitters name and address: ● Hermes Medical Solutions AB Strandbergsgatan 16 112 51 Stockholm Sweden
. Submitters telephone number
| Phone: | +46 8 19 03 25 |
|---|---|
| Cell: | +46 708 19 03 08 |
| E-mail: | joakim.arwidson@hermesmedical.com |
. Contact person
Joakim Arwidson VP Quality and Regulatory Hermes Medical Solutions AB Strandbergsgatan 16 112 51 Stockholm Sweden
- . Registration number 9710645
- B. Preparation date: 2018-05-30
C. Proprietary/Trade name, Common name, Classification name :
- Proprietary/Trade name . Hybrid3D v3.0
- . Common name Image processing systems
- . Classification name Emission Computer Tomography System, Class II, 21CFR892.1200
D. Legally marketed device (predicate device):
Following legally marketed device has been used for comparison.
- . Hybrid3D v2.0 (K171719)
E. Description of the device that is subject of this premarket notification :
Hvbrid3D
HERMES Hybrid3D is a reading and processing module for the advanced needs in medical imaging. It offers multi-modal (PET/CT/MR/SPECT) coregistration and interactive fusion of multiple datasets. HybridViewer 3D handles viewing and fusion of multi-sequence MRI studies with oblique orientation and allows switching between original and standard TCS view orientation as well as defining own slice directions. 3D seqmentation, cropping and interpolation techniques allow
4
complex tasks in VOI definition and can cover cases like cavities, splitting structures into subsections or logic operations (compute intersections, merge, grow). Results can be imported and exported as DICOM and are therefore available for research in 3rd party tools. Additionally, it provides tools for advanced 3D fusion rendering of studies and VOIs.
Lung Lobe Quantification
The Lung Lobe Quantification module in Hybrid3D, introduces an efficient and automated workflow solution to accurately compute 3D lobar anatomy from CT (with or without contrast). The workflow supports the addition of functional images (SPECT V/Q, SUV SPECT, CT iodine maps, hyperpolarized xenon MRI, etc.) to accurately relate lobar anatomy to function. No changes have been made to Lung Lobar Quantification since the previous release.
TumorFinder
The Tumor Finder wizard provides automatic segmentation of lesions in a PET study or a combined PET/CT study pair, based on criteria relative to a background volume placed in the liver or mediastinum. This reduces the time required for tumor delineation. It also provides both visual and statistical evaluation of tumor burden, which helps with comparing follow up studies.
SIRT
Selective Internal Radionuclide Therapy (SIRT), is currently used in the treatment of liver tumors either from primary liver cancer or metastatic disease (e.g. colorectal primary cancer). The SIRT wizard provides processing for SIRT planning and verification.
F. Intended use:
Hybrid3D that provides software applications used to process, display, analyze and manage nuclear medicine and other medical imaging data transferred from other workstation or acquisition stations.
Warning! The results generated by the SIRT function cannot be used to change a treatment plan after the treatment has been delivered, nor can the results be used to impact future treatment planning for any type of radiation therapy or chemotherapy. The SIRT function cannot be used for prospective treatment planning of initial treatment with microspheres in contradiction to the labeling of Class III radiation microsphere devices.
Warning! The results from the SIRT function using the partition model for dose planning cannot be used to change a clinical Y90 SIRT treatment plan, either before or after treatment. Nor can the results be used to impact future clinical treatment planning for any type of radiation therapy or chemotherapy. The SIRT function cannot be used for prospective treatment planning, initial or retreatment, with Y90 microspheres in contradiction to the labeling of the Class III radiation microspheres devices.
G. Technological characteristics:
The proposed device Hybrid3D has the same technological characteristics as the predicate device and the same indication for use.
H. Testing:
The tests for verification and validation followed Hermes Medical Solutions AB design controlled procedures. The Risk analysis was completed and risk control implemented to mitigate identified hazards. The testing results supports that all the software specifications have met the acceptance criteria.
5
I. Substantially Equivalent/Conclusions:
The proposed device Hybrid3Dv3.0and the predicate device Hybrid 3D v2.0 (K171719) have the same indication for use.
The proposed device will use similar technology and fundamental concepts and operation are also the same, as described in the 510(k) submission.
The comparisons between Hybrid 3D v3.0 and Hybrid 3D v2.0 (K171719) were part of the test procedure for V3.0 and showed good results.
Validation of the Hybrid3D SIRT has been made between the calculations performed by Hybrid3D and the results from spreadsheet calculations based on the formulae published by SIRTEX for the Resin Microspheres and BTG for the Glass Theraspheres.
- Lung Shunt was calculated from planar images. The results for Lung Shunt were identical.
- . The Prescribed Activity for Planning using Resin Microspheres using the BSA method were identical to 2 decimal places
- The Activity to Implant for Planning using Glass Microspheres using the PTV method were identical to 2 decimal places
- The Voxel Dose measured from the PETDose Map was identical to 2 decimal places ●
- The Voxel Dose measured from the SPECT Dose Map varied by up to 5% because the . methods used for normalization, by calculating the common field of view by the application and by the test procedure, differ slightly.
- . The values for Maximum Dose and Dose at 90% Volume D90%(Gy) differ because of the inherent inaccuracy of reading values manually from the Dose Volume Histogram. The test was performed only to establish that there were no fundamental errors in the calculations.
In summary, the Hybrid3Dv3.0 described in this submission is in our opinion substantially equivalent to the predicate devices.